Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioFocus Announces Agreement with ChanTest

Published: Thursday, February 07, 2013
Last Updated: Wednesday, February 06, 2013
Bookmark and Share
BioFocus expands ion channel offering.

BioFocus and ChanTest have announced an agreement which will enable BioFocus to offer ChanTest’s extensive cell line library (> 200 products) and Channel Panel™ profiling services.

This expands BioFocus’ offering in the fields of ion channel, GPCR and transporter targets for drug discovery.

“With access to ChanTest’s cell line collection and ion channel profiling, we have further augmented our suite of integrated drug discovery services, designed to deliver efficiency and success to our partners,” said Kate Hilyard, VP Biological Sciences, BioFocus.

Chris Mathes, Ph.D., M.B.A, Chief Commercial Officer, ChanTest, commented, “This collaboration with BioFocus fits well with ChanTest’s integrated CRO strategy, and we are delighted to partner with a company with such a strong reputation.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim
Under the terms of the agreement, BioFocus will apply its drug discovery services to an undisclosed target within Boehringer Ingelheim’s drug discovery portfolio.
Thursday, November 21, 2013
BioFocus Signs Agreement with Biogen Idec
The 3-year collaboration will focus on the identification and validation of novel targets in scleroderma.
Tuesday, November 12, 2013
BioFocus Signs Agreement with Aviva Investors
Pre-let agreement for construction of new laboratory and HQ building at Chesterford Research Park.
Thursday, September 05, 2013
BioFocus Receives Rapid Response Innovation Award from The Michael J. Fox Foundation
Grant will support the development of a novel Parkinson’s disease cell model.
Tuesday, June 25, 2013
BioFocus Launches Academic Engagement Initiative
Aim of the initiative is to identify the best new therapeutic strategy ideas from academic groups.
Wednesday, May 01, 2013
BioFocus Extends its Collaboration with The Michael J. Fox Foundation
BioFocus has extended its collaboration agreement for Parkinson’s Research.
Thursday, April 18, 2013
Peter Rehse joins BioFocus as Senior Director, Structural Biology
BioFocus today announced that Dr. Peter Rehse has joined the company and will be based at Chesterford Park, near Cambridge, UK.
Monday, February 11, 2013
BioFocus Achieves Milestone in its Drug Discovery Collaboration with UCB
Discovery milestone triggers payment from UCB and demonstrates BioFocus’ ability to support its clients.
Tuesday, December 04, 2012
BioFocus and Ono Sign a Drug Discovery Agreement
The collaboration agreement between Galapagos NV’s service division, BioFocus, and Ono Pharmaceutical Co., Ltd. will focus on discovering novel drugs in the field of CNS disorders.
Monday, September 03, 2012
BioFocus and Activiomics Announces Strategic Alliance
BioFocus expands its drug discovery offering with proteomics technology from Activiomics.
Thursday, July 26, 2012
BioFocus and Argenta Announce Drug Discovery Collaboration
Collaboration with AstraZeneca in respiratory and inflammatory disease.
Thursday, March 15, 2012
Almirall and BioFocus enter Research Alliance
Three-year integrated drug discovery alliance aims to identify drug development candidates for treating respiratory disease.
Wednesday, January 25, 2012
Argenta and BioFocus Announce Two-Year Extension Of Drug Discovery Collaboration with Genentech
Total potential value of the contract extension is up to £21.5 million (€23.4 million).
Monday, August 22, 2011
BioFocus and InterMed Discovery Announce Marketing Collaboration
The collaboration will offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries.
Wednesday, August 03, 2011
BioFocus and InterMed Discovery Announce Marketing Collaboration
IMD will make natural product screening libraries available and provide follow-on services to BioFocus.
Wednesday, July 20, 2011
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Porphyrins as Catalysts in Scalable Organic Reactions
This review covers the most relevant scalable porphyrin-catalysed procedures, showing how these compounds represent broad applications in chemistry.
CDC Updates Zika Recommendations
CDC has issued updated Zika recommendations and guidance for healthcare providers with a focus on sexual transmission.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Genome of 6000-Year-Old Barley Sequenced
Researchers have successfully sequenced the genome of Chalcolithic barley grains for the first time.
3D Models May Yield Ovarian Cancer Insights
Researchers are developing new tools to decipher ovarian cancer developments through a 3D printing technology.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!